Abstract: Diabetes is a major risk factor for cardiovascular disease (CVD), and cardiovascular related complications are the leading causes of death in patients with type 2 diabetes. Gglucagon-like peptid-1 receptor agonist (GLP-1 RA) as a new type of drug for the treatment of diabetes, can not only protect the myocardium, but also play a protective role in the cardiovascular system through relevant mechanisms. GLP-1 RA has different pharmacodynamic properties. In this review, the results of cardiovascular trials on GLP-1RA in recent years were reviewed, and the potential differences and potency of GLP-1 RA in the cardiovascular system are further discussed.